2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, Genomics, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Young Adult
PAPER

3887 Ultra-deep clonotype-based IG-NGS measurable residual disease dynamics across three fixed-duration strategies in chronic lymphocytic leukemia

Yuting Yan, MD, Jialu Wu2, Dandan Cao, PhD3, Weihao Chen4, Xinyi Zhang5, Tingyu of Wang6, Ying Yu7, Zhen Yu, MD8, Dehui Zou, MD9, Liang Huang, MD10, Victoria Lei11, Gang An, MD12, Lu-Gui Qiu, PhD13, Shuhua Yi, DO14
1 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 Genetron Health (Beijing) Co. Ltd., Beijing, China
4 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
9 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
11 Genetron Health (Beijing) Co. Ltd., Beijing, China
12 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
13 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
14 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Background: Frontline chronic lymphocytic leukemia (CLL) therapy has shifted toward targeted agents; however, deep remission after a finite treatment course remains clinically relevant. Flow cytometry (FCM) detects measurable residual disease (MRD) to 10-4(MRD4); Immunoglobulin-based next-generation sequencing (IG-NGS) extends sensitivity to 10-6 (MRD6), identifying residual clones in FCM-negative samples. Deeper MRD carries incremental prognostic value in fixed-duration regimens (CLL14; MURANO). We used IG-NGS to characterize measurable residual disease (MRD) depth, tissue concordance, and kinetics across three time-limited strategies.

Methods: We analyzed 103 previously untreated patients in three fixed-duration  FCR-backbone strategies: (1) standard FCR (fludarabine, cyclophosphamide, rituximab; 4-6 cycles); (2) the HAMBURGER regimen (continuous ibrutinib alternating with three intermittent FCR cycles administered on days 1–3 of cycles 1, 5, and 9; NCT03980002); (3) the STOP regimen (12-month zanubrutinib lead-in followed by four cycles zanubrutinib plus FCG (G=obinutuzumab), NCT05287984). Patient-specific IGH/IGK/IGL clonotypes were longitudinally tracked in peripheral blood (PB) and bone marrow (BM) using FlorenTrack™ (formerly Seq-MRD®), an ultra-deep clonotype-based IG-NGS MRD assay. uMRD4/uMRD5/uMRD6 required MRD below 10-4/10-5/10-6with the sample limit of detection reaching the corresponding threshold. Flow-NGS concordance, PB-BM  used strictly matched same-patient, same-date, same-tissue pairs.

Results: Among 753 post-treatment NGS samples, uMRD4/uMRD5/uMRD6 rates were 266/753 (35.3%)/205/749 (27.4%)/68/674 (10.1%). Across 592 identical FCM-NGS specimens, MRD4 agreement was 90.5% (kappa=0.801); NGS detected MRD4 in 47/246 (19.1%) FCM-negative samples, including 33/110 (30.0%) BM samples. Among 205 PB-BM pairs from 75 patients, continuous MRD correlated strongly (Spearman r=0.916); MRD4 agreement was 191/205 (93.2%; kappa=0.854), with PB-negative/BM-positive results in 12 pairs versus PB-positive/BM-negative results in 2 (McNemar P=.0129).

Best uMRD4/uMRD5/uMRD6 rates were 4/17 (23.5%)/3/17 (17.6%)/2/17 (11.8%) with FCR, 18/37 (48.6%)/11/37 (29.7%)/8/37 (21.6%) with HAMBURGER regimen, and 41/41 (100%)/39/41 (95.1%)/28/41 (68.3%) with STOP regimen (all overall P<.001). In 40 STOP-cohort pairs, tracked clonal burden decreased from 0.414 after zanubrutinib lead-in/before FCG to 4.07×10?6 after at least two zanubrutinib plus FCG (ZFCG) cycles, a median within-patient 8.1×104-fold reduction. Paired uMRD4 increased from 1/40 (2.5%) to 33/40 (82.5%; P<0.001). Among 87 patients with response and MRD4 data, 17/60 (28.3%) complete responders remained MRD4-positive, whereas 16/27 (59.3%) patients without complete response achieved uMRD4. MRD4 recurrence occurred in 7/11 (63.6%) HAMBURGER versus 1/32 (3.1%) ZFCG patients, rising at deeper thresholds. Treatment cohort was associated with progression-free survival (log-rank P<0.001); TP53 abnormality showed an exploratory association with inferior overall survival after cohort stratification (P=0.027). With limited follow-up time, no MRD4/5/6 variable remained significant after cohort adjustment and multiple testing.

Conclusions: Across three time-limited CLL strategies, ultra-deep clonotype NGS resolved disease missed by FCM and identified PB-BM discordance. Sequential STOP regimen achieved the deepest, most consistent molecular remissions among three fixed-duration strategies, but this should not be attributed to treatment sequencing alone: paired analysis localized most clonal clearance to the period after chemoimmunotherapy was added, indicating that chemotherapy-mediated debulking together with the stronger clearance of obinutuzumab relative to rituximab, while zanubrutinib lead-in first lowered tumor burden to enable it — additive contributions whose weights require randomized evaluation. FCM negativity at 10-4 is insufficient to guide discontinuation, since nearly one-third of FCM-negative marrows harbored NGS-detectable disease; Clinical response and molecular remission are not interchangeable and should be applied jointly in stopping rules. MRD recurrence after deep negativity precedes progression, supporting IG-NGS monitoring in fixed-duration CLL.

Yuting Yan, MD: No relevant conflicts of interest to declare.